Recent data strongly suggested that targeting BET BRDs will be beneficial for many diverse cancer types due to downregulation of oncogenes such as c-Myc (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011). Here, MYC is linked to cancer.